AstraZeneca agreed to license Dizal Pharmaceutical’s oral EGFR exon 20 insertion therapy, Zegfrovy (sunvozertinib), in a deal potentially worth up to $1.5 billion. AstraZeneca will pay $600 million upfront and additional milestone payments tied to development, regulatory, and sales. The drug is already approved in the US and China for previously treated NSCLC with EGFR exon 20 insertion mutations, and it is being pursued as a first-line option. Dizal’s WU-KONG28 Phase 3 results reported median progression-free survival of 10.3 months versus 7.5 months with platinum-doublet chemotherapy. Strategically, the licensing gives AstraZeneca a differentiated oral targeted therapy option that fits its existing EGFR portfolio while moving Dizal’s program into broader global development and commercialization.